Agennix Halves Headcount, Closes Houston Site, Following Talactoferrin Failure In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
German biotech Agennix makes drastic cuts following second late-stage clinical trial failure of its investigational oral immunotherapy talactoferrin.